Amgen, Sandoz Settle Clash on Blockbuster Drugs’ Biosimilars (1)

Amgen Inc. and Sandoz Group AG settled a patent-infringement lawsuit over biosimilar versions of Amgen’s Prolia and Xgeva bone-strengthening drugs, according to a New Jersey federal judge’s order.

Sandoz conceded as part of a confidential binding settlement term sheet that its biosimilars, Jubbonti and Wyost, infringe US Patent No. 7,364,736, according to Judge Christine P. O’Hearn’s order issued late Monday in the US District Court for the District of New Jersey. The order blocked Amgen’s rival treatments until Feb. 19, 2025.

The drugmakers also resolved the case’s remaining patent disputes, allowing Sandoz to launch its biosimilar products on May ...